Leidos expands production capacity to build thousands of cruise missiles for U.S. strike arsenal

Leidos is expanding production capacity to build thousands of cruise missiles for the U.S. under a framework agreement with the Department of War. The company plans to deliver the first weapons in 2027, with full-rate production starting in 2028. Leidos is investing in facilities, supply chain, and workforce to scale production quickly, with work concentrated in Alabama and Tennessee.

Original reporting
Published Nov 3, 2026, 2:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 3:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$LDOS
Bullish
medium confidence
Mentioned
$LDOS
Relevance
7/10
AlphAI data visualization · based on defence-industry.eu
Decision brief

The 30-second read

$LDOSBullishMed
01

Why it matters

It frames a multi-year ramp for LCCM deliveries (first in 2027 for test and evaluation, full-rate in 2028-2029) and notes ongoing Havoc Spear deliveries plus a separate 45-missile award with fall 2027 delivery expectations.

02

Market read

For LDOS, the actionable takeaway is improved visibility into missile program execution timelines and supply-chain scaling, though the article lacks contract dollar amounts and immediate financial guidance.

03

What to watch

Execution risks remain high for multi-year ramps, including supply-chain bottlenecks, qualification/test outcomes for LCCM, and potential program schedule changes by the Department of War/US Special Operations Command.

Relevance 7/10Novelty 6/10Timing: today’s defense-industry update, with delivery milestones extending into 2027-2029

Background

The piece describes Leidos expanding cruise-missile production capacity under a May 13 framework agreement and coordinating suppliers nationwide.

Company-level read

Ticker impact

$LDOSBullishMedium confidence
Context

Leidos plans to scale cruise missile production, targeting first LCCM deliveries for test and evaluation in 2027 and full-rate production in 2028-2029.

Expected impact

Likely modest upward bias as investors price improved execution visibility and industrial-base expansion, tempered by long-dated ramp and government procurement uncertainty.

Evidence & confidence

The article provides specific production timing (2027 test/eval, 2028-2029 full-rate) and references framework and follow-on missile awards, but it does not disclose contract values or immediate financial guidance that would drive a large repricing today.

Market effects

Supports the broader defense primes and missile-supply-chain theme, highlighting capacity buildouts and supplier coordination as a key constraint for long-range strike programs.

Concentrates production work in Huntsville, Alabama and McEwen, Tennessee, reinforcing regional defense manufacturing demand.

Signals sustained U.S. long-range strike procurement and industrial-base mobilization, which can influence expectations for missile-component suppliers and allied defense production capacity.

Counterpoint

Capacity announcements can reflect planning and supplier coordination rather than funded, near-term revenue; without contract values, the market may discount the impact.

Key entities

  • Leidos

    Defense contractor expanding cruise missile production capacity and coordinating a nationwide supplier network.

  • Department of War

    Referenced as the counterparty to a May 13 framework agreement for LCCM production.

  • U.S. Special Operations Command

    Referenced as awarding Leidos a summer 2026 contract for 45 missiles with deliveries expected to begin in fall 2027.

  • Pratt & Whitney

    Quoted discussing investment in propulsion capacity and advanced manufacturing for operational fleets and future programs.

  • Divergent

    Quoted executive highlighting urgency and information sharing among suppliers.

Related articles

$LDOSHighAI 8/10

Leidos stock falls revenue outlook disappoints

Leidos LDOS shares fell 2.1% premarket after Q3 earnings beat estimates but revenue missed expectations, leading to lowered 2026 revenue guidance. Adjusted earnings rose 19% to $3.62, while revenue increased to $4.63B. Health segment revenue declined 12%, offsetting growth in other areas. The company raised its adjusted earnings forecast but reduced revenue outlook, highlighting challenges in translating contract backlog into revenue growth.

$LDOSHighAI 8/10

Leidos raises FY26 adjusted EPS guidance to $12.50-$12.70

Leidos Holdings Inc. raised its FY26 adjusted EPS guidance to $12.50-$12.70 from $12.20-$12.50, citing improved profitability. Sales guidance was lowered to $18.000B-$18.200B from $18.200B-$18.400B due to the SES joint venture. Operating cash flow was increased to ~$1.90B from ~$1.85B. Q2 revenue grew 7% YoY to $4.56B, with record operating cash flow of $793M.

$LDOSMedAI 8/10

Leidos Q3 net income rises 12% to USD 413 million

Leidos reported a 12% rise in Q3 net income to USD 413 million, with diluted earnings up 16% to USD 3.28 per share and revenues reaching USD 4.63 billion. Operating cash flow declined 26% to USD 523 million, while funded backlog grew 22% to USD 11.1 billion. The company adjusted FY26 revenue guidance to USD 18 billion from USD 18.2 billion, reflecting a joint venture and current outlook.